» Articles » PMID: 38903348

Reconstructive Limb Salvage After COVID-19-Induced Gangrene and Amputation

Overview
Journal Cureus
Date 2024 Jun 21
PMID 38903348
Authors
Affiliations
Soon will be listed here.
Abstract

This case series describes the clinical course and reconstructive methods utilized for patients with diabetes and significant gangrene and necrosis following coronavirus disease 2019 (COVID-19) infection. COVID-19 produces mainly respiratory symptoms but has a variety of atypical presentations and sequelae. Serious complications are increased in patients with underlying medical conditions such as diabetes mellitus. By generating a prothrombotic milieu, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases the risk for arterial and venous thromboses. Inflammatory damage and micro-thromboses are thought to contribute to acro-ischemia, colloquially known as 'COVID toes,' which presents cutaneously as chilblain-like lesions. Necrosis can be severe and devastating, often resulting in major amputation. Two exemplary case reports are presented herein: first, a 57-year-old female presented for vascular evaluation with pedal gangrene to the midfoot one month after developing painful discoloration in her right toe. After angioplasty restored pedal blood flow, she received a transmetatarsal amputation (TMA) with a local tissue flap. Second, a 41-year-old female presented for vascular evaluation with extensive pedal gangrene three months after hospitalization for COVID-19. After arteriotomy improved pedal blood flow, she underwent a Lisfranc amputation followed by superficial circumflex iliac artery perforator (SCIP) flap reconstruction. Sufficient evidence suggests that COVID-19 impairs microcirculatory function and can be especially detrimental in diabetic patients. Reconstructive techniques in patients with severe gangrene with COVID toes help patients regain functionality.

References
1.
Sharp C, BESSMAN A, Wagner Jr F, Garland D . Microbiology of deep tissue in diabetic gangrene. Diabetes Care. 1978; 1(5):289-92. DOI: 10.2337/diacare.1.5.289. View

2.
McCleskey P, Zimmerman B, Lieberman A, Liu L, Chen C, Gorouhi F . Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic. JAMA Dermatol. 2021; 157(8):947-953. PMC: 8223123. DOI: 10.1001/jamadermatol.2021.2120. View

3.
Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C . Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. JAMA Dermatol. 2020; 157(2):202-206. PMC: 7689569. DOI: 10.1001/jamadermatol.2020.4324. View

4.
Singh S, Zuwasti U, Haas C . Coronavirus-Associated Coagulopathy: Lessons From SARS-CoV1 and MERS-CoV for the Current SARS-CoV2 Pandemic. Cureus. 2020; 12(11):e11310. PMC: 7714748. DOI: 10.7759/cureus.11310. View

5.
Oudkerk M, Buller H, Kuijpers D, van Es N, Oudkerk S, McLoud T . Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology. 2020; 297(1):E216-E222. PMC: 7233406. DOI: 10.1148/radiol.2020201629. View